GIPR and obesity disorder: There has been great interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) as a means of augmenting the insulinotropic and anti-obesity action of glucagon-like peptide-1 receptor (GLP-1R) agonists.